Webinar Overview
If you’ve identified a potential RNA target, you can significantly accelerate and optimize hit identification by using a highly selective in vivo screening strategy when hunting for the ideal Antisense Oligonucleotide (ASO) therapy.
In this webinar you will hear from our experts about how a holistic approach to ASO therapy development can lead to a more efficient path to clinic through:
- Relevant disease models including patient-derived cells
- Lead optimization
- Predictive efficacy
Webinar Presenters
David Fischer, PhD
Chief Technology Officer
Charles River
Roxana Redis, PhD
Group Leader, Advanced Modalities
Charles River
Michael V. Templin, PhD, DABT
Director, Senior Principal Scientific Advisor
Charles River
Additional Information
- RNA-based Drug Discovery for Spinal Muscular Atrophy (Download the Publication)
- Learn More About Bioinformatics Services
- ASOs: A Short History on the Diversity of Clinical Applications (Eureka Blog)